-
Capivasertib Extends Progression-Free Survival in Hormone Receptor-Positive Breast CancerThe new AKT inhibitor doubled progression-free survival when added to treatment with Faslodex.
by Eric Fitzsimmons
-
Pregnancy After a Breast Cancer DiagnosisStudy finds pausing endocrine therapy is safe for early-stage breast cancer patients eager to expand their families.
by Thomas Celona
-
Disparities in Breast Cancer Outcomes for Black Women Despite Similar Recurrence ScoresBlack breast cancer patients had worse outcomes in a recent study, even when cancer features aligned with white patients.
by Eric Fitzsimmons
Cancer Talk
Delaying Treatment Resistance
Adding a CDK 4/6 inhibitor extends progression-free survival for people with metastatic HR-positive, HER2-positive breast cancer.
by Thomas Celona
2024: The Year in Cancer NewsThe Cancer Today editors share the most impactful reporting on cancer research from 2024.
by Cancer Today staff
Cancer Today Editors’ Picks: 2024Our favorite Cancer Today stories from 2024, as picked by the editors.
Rethinking the Role of RadiationChest radiation may not be necessary for people with intermediate-risk breast cancer.
by Thomas Celona
From the AACR
-
AACR Grant Propels Progress in Immunotherapy ResearchA grant from the American Association for Cancer Research (AACR) helped Marco Ruella, MD, develop a new approach to immunotherapy.
-
Self-screening for Cancer: Home Sweet HomeNew cervical cancer self-screening options and a portable blood test device could lead to changes in at-home cancer screening.
Video
Alexis Browning
